In today’s NewsFlash Roundup, Massachusetts gets in on a pricing complaint against Wyeth, Biogen starts a Phase 3 trial, Cambium merges and GTC receives another delisting notice.
- Biogen starts Phase 3 trial of MS treatment
- GTC receives second delisting notice
- Pilot study shows promise for combination weight loss device
- Mass. joins in Wyeth drug complaint
- Babcock Power names LeClair president, CEO
- Airvana sees benefit from Nortel liquidation
- Cambium, Voyager Learning merge education tech
- Book review: “Bricklin on Technology,” by Dan Bricklin
RSS Feeds
